Skip to main content

Table 3 Comparison of Alb, NLR, and BMI, and their change during NAC among the decreased, maintained, and increased SMI groups

From: Skeletal muscle loss during neoadjuvant chemotherapy predicts poor prognosis in patients with breast cancer

 

SMI

 
 

Decreased

Maintained

Increased

 

Variables

n = 40

n = 53

n = 48

p value

Pre-Alb (g/dl)

4.59 ± 0.29

4.51 ± 0.28

4.42 ± 0.31

0.65

Post-Alb (g/dl)

4.20 ± 0.34

4.01 ± 0.31

4.03 ± 0.43

0.52

Change in Alb (mean ± SD)

−0.31 ± 0.38

−0.44 ± 0.34

−0.33 ± 0.36

0.18

Pre-NLR

2.77 ± 2.13

2.49 ± 1.38

2.38 ± 1.04

0.48

Post-NLR

3.40 ± 1.79

3.02 ± 1.59

2.72 ± 1.44

0.14

Change in NLR (mean ± SD)

0.62 ± 1.99

0.54 ± 1.74

0.20 ± 1.31

0.71

Pre-BMI

22.2 ± 3.51

22.0 ± 2.98

22.7 ± 4.10

0.64

Post-BMI

22.0 ± 3.51

22.0 ± 3.10

22.9 ± 4.45

0.64

Percent change in BMI (mean ± SD)

−1.11 ± 8.26

−0.22 ± 3.96

0.91 ± 5.74

0.28

  1. Alb Serum albumin level, NLR Neutrophil-to-lymphocyte ratio, BMI Body mass index, NAC Neoadjuvant chemotherapy, SMI Skeletal muscle index